Posted by Michael Wonder on 24 Jun 2020
ICER provides first update to pricing models for remdesivir as a treatment for COVID-19
24 June 2020 - Updated cost-recovery benchmark price now framed as a range with maximum of $1,600/10 day regimen when incorporating assumptions regarding manufacturer’s 2020 development expenses, uptake of remdesivir, and consideration of early examples of real-world generic pricing.
The Institute for Clinical and Economic Review (ICER) today released updated analyses to inform public debate of pricing for remdesivir (Gilead Sciences) and other future treatments of COVID-19.
Adhering to ICER’s adapted methodology for evaluating treatments for a pandemic, the ICER-COVID models comprise two alternative pricing paradigms for COVID-19 treatments: 1) “cost recovery” for the manufacturer, in which the price is adequate to return the costs of production of the drug and may also recoup drug-specific development costs; and 2) traditional cost-effectiveness analyses looking at the incremental health benefits and costs within the health system. ICER had previously published results from an initial iteration of the ICER-COVID models on May 1, and today’s updated models incorporate changes based on recent clinical data, updated cost estimates, public comments, and interactions with the manufacturer.
